| Abstract ID |
| 20260071 |
| Category |
| Knee: ACL |
| Preferable Presentation |
| Both |
| Title |
| ANALGESIC EFFICACY OF INTRAVENOUS NEFOPAM AFTER ARTHROSCOPIC ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION: A PROSPECTIVE, TRIPLE-BLIND, RANDOMIZED CONTROLLED TRIAL |
| Author |
|
| Presenter |
| wiset tangphromphan |
| Abstract |
| Background: Arthroscopic anterior cruciate ligament reconstruction (ACLR) can cause significant postoperative pain. Nefopam is a centrally acting non-opioid analgesic often used in multimodal analgesia (MMA) regimens to improve recovery. Objectives: The primary objective of this study was to evaluate the analgesic efficacy of intravenous nefopam by measuring the Verbal Numerical Rating Scale (VNRS) pain score at 24 hours postoperatively. Secondary objectives included assessing morphine consumption, postoperative adverse effects, and quality of recovery. Study Design: This prospective, triple-blind, randomized controlled trial initially enrolled 52 patients undergoing ACLR, of whom 50 were included in the final analysis (25 per group). Two patients were excluded due to spinal anesthesia failure requiring a change in anesthesia method. The Nefopam group received intravenous nefopam 20 mg every 6 hours for 24 hours, while the Control group received placebo. All patients received standardized MMA including paracetamol, ketorolac, and patient-controlled analgesia morphine. Results: At 24 hours postoperatively, the mean VNRS pain score at rest was lower in the Nefopam group than in the Control group (1.08 ± 1.58 vs. 1.84 ± 1.80), although the difference was not statistically significant (p = 0.1186). Cumulative 24-hour morphine consumption was comparable between groups (9.96 ± 9.47 mg vs. 9.92 ± 6.31 mg; p = 0.9860). The incidence of adverse effects did not differ significantly between groups. Conclusion: The addition of intravenous nefopam to a standard multimodal analgesic regimen did not provide additional analgesic benefit beyond standard multimodal analgesia following arthroscopic ACLR. |